LCZ696 is a new drug under development by Novartis. The drug is believed to be a significant improvement over existing drugs; it not only inhibits hormones that constrict blood vessels like existing medications but also boosts the production of beneficial hormones. The clinical trials showed a 20% reduction in death from cardiovascular causes, a 16% reduction in death from any cause and also reduced hospitalization for heart failure by 1/5th among participants.

The highly successful results in the clinical trials led the researchers to end the trial at an early stage after 27 months. Novartis plans to apply for a license in early 2015, which means that the drug will be available in markets the same year provided the license is granted.

Download GKToday's Android App for Current Affairs updates and quizzes.